Allogene Therapeutics, Inc. (ALLO)
$
1.17
+0.06 (5.13%)
Key metrics
Financial statements
Free cash flow per share
-0.7930
Market cap
259.6 Million
Price to sales ratio
0
Debt to equity
0.2300
Current ratio
8.9236
Income quality
0.7293
Average inventory
0
ROE
-0.5864
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company that focuses on the development and commercialization of genetically engineered allogeneic T cell therapies to combat cancer. The company reported depreciation and amortization expenses of $13,639,000.00 reflecting the wear and tear of its assets, which is a vital element in assessing its financial health. The weighted average number of shares outstanding is 194,812,000.00 highlighting the company's shareholder base and its appeal to investors. Allogene’s operating expenses amount to $273,221,000.00 encompassing various operational costs incurred during its innovative development processes. The cost of revenue for the company is $13,639,000.00 showcasing its production and operational expenses, which are crucial to its overall profitability. Consequently, the gross profit stands at $22,000.00 highlighting the company's financial performance from core operations as it champions the fight against cancer. The company develops, manufactures, and commercializes products like UCART19 for R/R CD19 positive B-cell ALL, and several other promising candidates for various cancers, thus forming a diverse product portfolio that underscores its dedication to improving patient outcomes. The stock is affordable at $1.17 suitable for budget-conscious investors, making it accessible to a wider range of potential shareholders. Additionally, the stock has a high average trading volume of 3,985,933.00 indicating strong liquidity, which is often a desirable trait for active traders. With a market capitalization of $259,586,027.00 the company is classified as a small-cap player, positioning it uniquely within the market. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Moreover, it belongs to the Healthcare sector, driving innovation and growth, which enhances its reputation and attractiveness as an investment option. Through strategic collaborations and groundbreaking research, Allogene Therapeutics, Inc. continues to be a forward-thinking entity in the competitive field of immuno-oncology.
Is Allogene Therapeutics, Inc. (ALLO) a good investment?
Investing in Allogene Therapeutics, Inc. (ALLO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Allogene Therapeutics, Inc. (ALLO)'s stock forecast?
Analysts predict Allogene Therapeutics, Inc. stock to fluctuate between $0.86 (low) and $3.78 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Allogene Therapeutics, Inc.'s market capitalization?
As of 2025-09-11, Allogene Therapeutics, Inc.'s market cap is $259,586,027, based on 221,868,399 outstanding shares.
How does Allogene Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Allogene Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Allogene Therapeutics, Inc. (ALLO) stock?
To buy Allogene Therapeutics, Inc. (ALLO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALLO. Place an order (Market, Limit, etc.).
What is the best time to invest in Allogene Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Allogene Therapeutics, Inc. perform in the last earnings report?
Revenue: $22,000 | EPS: -$1.32 | Growth: -36.84%.
Where can I find Allogene Therapeutics, Inc.'s investor relations reports?
Visit https://www.allogene.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Allogene Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Allogene Therapeutics, Inc. stock?
All-time high: $27.86 (2021-09-23) | All-time low: $0.86 (2025-05-14).
What are the key trends affecting Allogene Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.
globenewswire.com
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in one upcoming investor conference in September.
seekingalpha.com
I maintain a 'Buy' rating on Allogene Therapeutics, as their diverse allogeneic cell therapy pipeline shows encouraging early data and pivotal trials are progressing. ALLO's financial position remains solid, with over $300 million in liquidity, sufficient to reach key data catalysts through 2027 despite brisk cash burn. The upcoming ALPHA3 futility analysis in 1H 2026 is a critical catalyst; positive MRD data could significantly revalue the stock from current depressed levels.
zacks.com
ALLO posts a narrower second-quarter 2025 loss. The company advances multiple CAR T programs targeting cancer and autoimmune diseases.
seekingalpha.com
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q2 2025 Earnings Conference Call August 13, 2025 5:00 PM ET Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy Officer David D. Chang - Co-Founder, President, CEO & Director Geoffrey M.
globenewswire.com
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the second quarter 2025 financial results and provide a business update on August 13, 2025, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.
zacks.com
J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.
zacks.com
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?
globenewswire.com
SOUTH SAN FRANCISCO, Calif., June 01, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in renal cell carcinoma (RCC) during an oral presentation at the 2025 ASCO Annual Meeting. The Phase 1 TRAVERSE trial enrolled patients with advanced or metastatic renal cell RCC. Leveraging the proprietary Dagger® technology to enable robust CAR T cell expansion, it stands as the first and only allogeneic CAR T product to show promise in treating solid tumors. The presentation focused on the Phase 1b expansion cohort from the Phase 1 TRAVERSE study in which patients were treated with a standard regimen of cyclophosphamide and fludarabine followed by a single dose of 80 million AlloCAR T™ cells.
seekingalpha.com
Allogene's off-the-shelf CAR-T therapies offer scalable, rapid solutions with a diversified pipeline targeting hematologic malignancies, solid tumors, and autoimmune diseases. Upcoming ASCO data, especially for ALLO-316 in solid tumors, could be a major catalyst and validate Allogene's platform for broader indications. Despite immense upside potential, significant risks remain: safety, execution, regulatory uncertainty, and likely dilution due to future fundraising needs.
See all news
